ArticleBone marrow transplantation2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma.
Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.Cancer · 2026Review
- Dual target combination therapy demonstrates promise in extramedullary myeloma.Translational cancer research · 2026Article
- CAR T-cells in multiple myeloma: the race to the start line.Bone marrow transplantation · 2026Review
- Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026Review
- Therapeutic options for extramedullary involvement in multiple myeloma.Clinical and experimental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T cell therapy is effective for multiple myeloma (MM), yet patients with plasmacytomas, either paraskeletal disease (PSD) or extramedullary disease (EMD), have poorer outcomes. To better distinguish the effects of EMD and PSD on outcomes, we conducted a single-center, retrospective study of 134 relapsed/refractory MM patients treated with CAR T cells. With a median follow-up of 30.2 months, patients with EMD (n = 34) had significantly worse progression-free survival (PFS) and overall survival (OS) than those with bone marrow-only disease (n = 75): PFS was 24.2 months vs. 9.0 months (HR 2.15, 95% CI 1.31-3.54), and OS was not reached vs. 24.0 months (HR 3.79, 95% CI 1.81-7.94). In contrast, patients with PSD did not experience significantly shorter PFS or OS. Among patients with EMD, those with high extramedullary tumor burden had a lower overall response rate (ORR). For extramedullary tumor burden <25 cm
Indexed as
Identifiers
40319194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.